Background
The manufacturer (Alexza Pharmaceuticals) was invited to submit evidence for this single technology appraisal in January 2013.
In January 2013 the manufacturer informed NICE that they would not be making a submission for this appraisal. The manufacturer said that they have received the marketing authorisation for loxapine inhalation (Adusave) but that this restricts administration to adults with mild to moderate agitation associated with schizophrenia and bipolar disorder and to the hospital setting. The manufacturer stated that there is insufficient evidence available to develop the appropriate analytical model required to estimate cost effectiveness in line with NICE single technology appraisal procedures.
NICE has therefore terminated this single technology appraisal.